SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery

Phase 3 Withdrawn Stefan Holubar MD MS FACS, FASCRS

Non-randomizedParallel-groupOpen-labelPrevention

Summary

Aim to determine if aspirin 81 mg orally twice daily is effective and safe as an extended VTE chemoprophylaxis agent after major abdominal surgery for IBD patients. Study will perform an open label trial of aspirin for VTE prophylaxis compared standard of care.

Timeline

Start: 2024-06-01
Primary completion: 2025-05-31
Completion: 2026-01-01

Outcome

Outcome not reported

Stopped: “Limited Resources”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aspirin	Small molecule	81 mg	Oral

SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery

Summary

Timeline

Outcome

Drugs

Indications